Success Stories: A Chemist from India Earns EB-1A Approval despite RFE

Client’s Testimonial:

“Thank You Very Much For Your Continuous Efforts And Help”

On September 9^th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Quality Control Chemist in the Field of Chemical Sciences (Approval Notice).

General Field: Chemical Sciences

Position at the Time of Case Filing: Quality Control Chemist

Country of Origin: India

State of Residence at the Time of Filing: Florida

Approval Notice Date: September 9^th, 2025

Processing Time: 18 months, 13 days

Case Summary:

North America Immigration Law Group (NAILG) is delighted to announce the approval of an EB-1A (Alien of Extraordinary Ability) petition for a quality control chemist from India specializing in chemical sciences. At the time of filing, the client was employed as a quality control chemist in the pharmaceutical sector, where he applied advanced chemical techniques to ensure drug quality and safety. After carefully presenting his record of impactful research and professional service, we filed his petition, which was approved in 18 months and 13 days. With our help, the client secured success despite receiving an RFE.

Proposed Endeavor: Advancing Chemical Sciences for Drug Development and Human Health

The client’s proposed endeavor focuses on conducting innovative research in chemical sciences to improve synthetic methodologies, catalysis, and medicinal chemistry applications. His work provides a foundation for developing new therapeutic agents, advancing drug design, and contributing to public health. With applications ranging from cardiovascular disease treatment to wastewater remediation and nanomaterials, his research directly supports the United States’ priorities in healthcare, environmental sustainability, and pharmaceutical innovation.

Notable Achievements Supporting the Petition
NAILG emphasized the following accomplishments to demonstrate his eligibility:

Education and Training: Holds a Ph.D. in chemistry with expertise spanning synthetic chemistry, medicinal chemistry, and catalysis.
Publications: Authored 27 peer-reviewed journal articles (5 first-authored), published in selective venues in chemistry and pharmaceutical sciences.
Citations: His work has been cited 567 times, placing him in the top 1% of most-cited researchers in chemistry over the past decade. Several of his articles rank among the top 10% most-cited works in the field.
Peer Review Service: Conducted at least 61 reviews for respected journals, including those ranked among the top in medicinal and organic chemistry, reflecting his recognized expertise. He also serves on editorial boards, underscoring his influence in maintaining research standards.
Global Recognition: His work has been cited by researchers in more than 44 countries across six continents, proving its broad international influence.

Expert Recognition

The client received six recommendation letters. A supporting expert letter described his impact on drug development as follows:

“Based on [The Client]’s outstanding research achievements in the past, I believe that he will continue to contribute greatly to his field and the United States scientific community.”

EB-1A Approval and Outlook

The approval of this EB-1A petition affirms the significance of the client’s contributions and his potential for continued impact in chemical sciences. NAILG is proud to have represented this accomplished researcher. His ongoing work will strengthen drug development, support pharmaceutical safety, and advance chemical innovations critical to the United States’ scientific and public health interests.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.